PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
Por:
Karachaliou, N, Cardona, A, Cao, MG, Gimenez-Capitan, A, Drozdowskyj, A, Aldeguer, E, Lopez-Vivanco, G, Sanchez-Torres, JM, Gil, MD, Molina-Vila, M and Rosell, R
Publicada:
1 nov 2017
Resumen:
Filiaciones:
Karachaliou, N:
Hosp Univ Sagrat Cor, Grp Quironsalud, Inst Oncol Dr Rosell Ior, Barcelona, Spain
Cardona, A:
Fdn Clin & Appl Canc Res FICMAC, Clin & Translat Oncol Grp, Bogota, Colombia
Cao, MG:
Inst Oncol Dr Rosell Ior, Quiron Dexeus Univ Inst, Barcelona, Spain
Gimenez-Capitan, A:
Pangaea Oncol, Lab Mol Biol, Barcelona, Spain
Drozdowskyj, A:
Pivotal, Madrid, Spain
Aldeguer, E:
Pangaea Oncol, Lab Mol Biol, Barcelona, Spain
Lopez-Vivanco, G:
Hosp Cruces, Oncol, Baracaldo, Spain
Sanchez-Torres, JM:
Hosp Univ La Princesa, Oncol Med, Madrid, Spain
Gil, MD:
Inst Oncol Dr Rosell Ior, Quiron Dexeus Univ Inst, Barcelona, Spain
Molina-Vila, M:
Pangaea Oncol, Lab Mol Biol, Barcelona, Spain
:
Germans Trias & Pujol Hlth Sci Inst & Hosp, Canc Biol & Precis Med Program, Catalan Inst Oncol, Badalona, Spain
|